Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Drugs Aging. 2022 Apr;39(4):257-269. doi: 10.1007/s40266-022-00934-1. Epub 2022 Mar 25.
Neuroendocrine tumors are a rare and heterogenous group of neoplasms that arise from hormone-producing cells throughout the body, with the greatest increase in incidence occurring among older adults aged ≥ 65 years. Despite this, there is currently a lack of data regarding the safety and efficacy of systemic treatment for older adults with neuroendocrine tumors. In this review, we provide a synopsis of the current standard-of-care pharmacotherapeutic treatments for neuroendocrine tumors, with an emphasis on available data in older adults. The benefits of various systemic options such as somatostatin analogs, tryptophan hydroxylase inhibition, molecular targeted agents, peptide receptor radionuclide therapy, and chemotherapy were similar between older adults compared to younger patients. However, real-world data regarding tolerance in the older adult population with neuroendocrine tumors are needed. Future development of novel systemic therapies in the neuroendocrine tumor treatment landscape and their inclusion of and potential impact on older adults living with neuroendocrine tumors is warranted.
神经内分泌肿瘤是一组罕见且异质性的肿瘤，起源于全身产生激素的细胞，发病率最高的是年龄≥65 岁的老年人。尽管如此，目前关于老年神经内分泌肿瘤患者系统治疗的安全性和疗效的数据仍然缺乏。在这篇综述中，我们提供了神经内分泌肿瘤当前标准治疗的药物治疗概述，重点介绍了老年人的可用数据。与年轻患者相比，各种全身治疗方案（如生长抑素类似物、色氨酸羟化酶抑制、分子靶向药物、肽受体放射性核素治疗和化疗）的获益相似。然而，仍需要关于老年神经内分泌肿瘤患者人群中耐受性的真实世界数据。在神经内分泌肿瘤治疗领域，新型系统治疗方法的未来发展及其对患有神经内分泌肿瘤的老年人的纳入和潜在影响是必要的。
